The estimated Net Worth of Junlin Ho is at least $1.94 Milion dollars as of 17 June 2024. Ms Ho owns over 4,695 units of Scholar Rock Corp stock worth over $1,773,420 and over the last 3 years she sold SRRK stock worth over $163,761.
Ms has made over 3 trades of the Scholar Rock Corp stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 4,695 units of SRRK stock worth $42,161 on 17 June 2024.
The largest trade she's ever made was selling 4,695 units of Scholar Rock Corp stock on 17 June 2024 worth over $42,161. On average, Ms trades about 1,237 units every 15 days since 2022. As of 17 June 2024 she still owns at least 204,076 units of Scholar Rock Corp stock.
You can see the complete history of Ms Ho stock trades at the bottom of the page.
Junlin Ho J.D. is the Gen. Counsel & Corp. Sec. at Scholar Rock Corp.
Ms D is 42, she's been the Gen. Counsel & Corp. Sec. of Scholar Rock Corp since . There are 13 older and no younger executives at Scholar Rock Corp. The oldest executive at Scholar Rock Holding Corp is Michael Gilman, 65, who is the Independent Director.
Over the last 6 years, insiders at Scholar Rock Corp have traded over $8,613,447 worth of Scholar Rock Corp stock and bought 8,895,194 units worth $64,726,758 . The most active insiders traders include Timothy A Springer, Srinivas Akkaraju a Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of $1,953,616. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth $13,538.
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s
Scholar Rock Corp executives and other stock owners filed with the SEC include: